...
首页> 外文期刊>Current pharmaceutical design >Mitochondrial biogenesis: a therapeutic target for neurodevelopmental disorders and neurodegenerative diseases.
【24h】

Mitochondrial biogenesis: a therapeutic target for neurodevelopmental disorders and neurodegenerative diseases.

机译:线粒体生物发生:神经发育障碍和神经退行性疾病的治疗靶标。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In the developing and mature brain, mitochondria act as central hubs for distinct but interwined pathways, necessary for neural development, survival, activity, connectivity and plasticity. In neurons, mitochondria assume diverse functions, such as energy production in the form of ATP, calcium buffering and generation of reactive oxygen species. Mitochondrial dysfunction contributes to a range of neurodevelopmental and neurodegenerative diseases, making mitochondria a potential target for pharmacological-based therapies. Pathogenesis associated with these diseases is accompanied by an increase in mitochondrial mass, a quantitative increase to overcome a qualitative deficiency due to mutated mitochondrial proteins that are either nuclear- or mitochondrial-encoded. This compensatory biological response is maladaptive, as it fails to sufficiently augment the bioenergetically functional mitochondrial mass and correct for the ATP deficit. Since regulation of neuronal mitochondrial biogenesis has been scantily investigated, our current understanding on the network of transcriptional regulators, co-activators and signaling regulators mainly derives from other cellular systems. The purpose of this review is to present the current state of our knowledge and understanding of the transcriptional and signaling cascades controlling neuronal mitochondrial biogenesis and the various therapeutic approaches to enhance the functional mitochondrial mass in the context of neurodevelopmental disorders and adult-onset neurodegenerative diseases.
机译:在发育中和成熟的大脑中,线粒体充当独特但相互联系的途径的中心枢纽,这是神经发育,生存,活动,连接性和可塑性所必需的。在神经元中,线粒体承担多种功能,例如以ATP形式产生能量,钙缓冲和活性氧种类的产生。线粒体功能障碍导致一系列神经发育和神经退行性疾病,从而使线粒体成为基于药物治疗的潜在靶标。与这些疾病相关的发病机理伴随着线粒体质量的增加,为了克服由于核或线粒体编码的突变的线粒体蛋白而导致的定性缺陷,线粒体的数量增加。这种补偿性生物学反应具有适应不良性,因为它不能充分增加生物能功能性线粒体的质量并不能纠正ATP的不足。由于已经对神经元线粒体生物发生的调控进行了详尽的研究,因此,我们目前对转录调节因子,共激活因子和信号调节因子网络的了解主要来自其他细胞系统。这篇综述的目的是介绍我们对控制神经元线粒体生物发生的转录和信号级联反应以及在神经发育障碍和成年发作的神经退行性疾病背景下增强功能性线粒体质量的各种治疗方法的知识和了解的当前状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号